WCO-IOF 2016: Denosumab versus zoledronic acid following oral bisphosphonate therapy

Study Type:Randomized Trial

OE Level Evidence:N/A

Journal Level of Evidence:N/A

A randomized double-blind study of denosumab (DMAB) compared with zoledronic acid (ZOL) in postmenopausal women with osteoporosis previously treated with oral bisphosphonates

Contributing Authors: SR Cummings P Miller JY Reginster HG Bone E Czerwinski MA Bolognese RB Wagman C Wang JP Brown J Malouf N Pannacciulli BS Nedergaard A Singer

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

CONFERENCE ACE REPORTS

This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.

Access conference website and list of abstracts.